EUVIMEDEUVIMED entdecken
Crossref

Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice

Mengya Chen iD, Nan Zhao, Wenke Shi, Yun Xing, Shiqiang Liu, Xianxian Meng, Lanlan Li, Heng Zhang, Yanyan Meng, Saiyang Xie, Wei Deng iD

Cardiovascular Research · 2025

DOI: 10.1093/cvr/cvaf005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Mengya Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan 430060, China. Hauptthemen laut MEDLINE: Amino Acids, Branched-Chain, Myocardial Infarction, Glucagon-Like Peptide-1 Receptor Agonists, Myocytes, Cardiac. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Key R&D Program of China, Regional Innovation and Development Joint Fund of National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

A novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist, tirzepatide (LY3298176, TZP), has been developed to treat Type 2 diabetes mellitus (T2DM). In ischaemic heart diseases, TZP is involved in cardiac metabolic processes. However, its efficacy and safety in treating heart failure (HF) following myocardial infarction (MI) remain uncertain. Methods and results Herein, 12 week C57BL/6J mice were subjected to MI surgery, followed by administration of TZP. The effects of TZP on cardiac function and metabolism were thoroughly assessed by physiological, histological, and cellular analyses. Downstream effectors of TZP were screened through untargeted metabolomics analysis and molecular docking. Construct a lower branched chain amino acid (BCAA) diet model to determine whether TZP’s cardioprotective effect is associated with reducing BCAA levels. Our results demonstrated that TZP reduced mortality following MI, decreased the infarct area, and attenuated cardiomyocyte necrosis. Pathological evaluation of cardiac tissues demonstrated increased fibrosis repair and decreased inflammatory infiltration. Mechanistically, untargeted metabolomics analysis uncovered a positive correlation between TZP and the BCAA catabolism pathway. The molecular docking verified that TZP could bind with branched-chain keto acid dehydrogenase E1 subunit α (BCKDHA). TZP reduced BCKDHA phosphorylation at S293, enhanced BCAA catabolism, and inhibited the activation of metabolism by activating rapamycin (mTOR) signalling pathway. Furthermore, mice fed a low-BCAA diet post-MI demonstrated reduced cardiomyocyte necrosis, increased fibrosis repair, and decreased inflammatory infiltration. These cardioprotective effects were further enhanced when used synergistically with TZP.

Conclusion

Taken together, our findings provide new perspectives on the unrecognized role of TZP in cardiac protection. TZP enhanced BCAA catabolism and attenuated BCAA/mTOR signalling pathway in MI mice. Consequently, this study may present novel therapeutic options for patients with HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amino Acids, Branched-ChainMyocardial InfarctionGlucagon-Like Peptide-1 Receptor AgonistsMyocytes, CardiacEnergy MetabolismGlucagon-Like Peptide-1 ReceptorGastric Inhibitory PolypeptideIncretinsAnimalsMice, Inbred C57BLMaleDisease Models, AnimalSignal TransductionMolecular Docking SimulationTOR Serine-Threonine KinasesVentricular Function, LeftFibrosis3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)Tirzepatide

Stichwörter der Autor:innen

BCAA catabolismHeart failureMyocardial infarctionTirzepatide

Substanzen

Amino Acids, Branched-ChainGlucagon-Like Peptide-1 Receptor AgonistsTOR Serine-Threonine KinasesGlucagon-Like Peptide-1 ReceptorGastric Inhibitory PolypeptideGlp1r protein, mousemTOR protein, mouse3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)IncretinsTirzepatide

Autor:innen und Institutionen

  • Department of Cardiology, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan 430060, China.
  • Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan 430060, China.

ORCID-Profile: Mengya Chen, Wei Deng

Förderung

  • National Key R&D Program of China
  • Regional Innovation and Development Joint Fund of National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Chen, M., Zhao, N., Shi, W., Xing, Y., Liu, S., Meng, X., Li, L., Zhang, H., Meng, Y., Xie, S., & Deng, W. (2025). Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf005

Vancouver

Chen M, Zhao N, Shi W, Xing Y, Liu S, Meng X, et al. Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf005

BibTeX
@article{Chen2025,
  author = {Chen, Mengya and Zhao, Nan and Shi, Wenke and Xing, Yun and Liu, Shiqiang and Meng, Xianxian and Li, Lanlan and Zhang, Heng and Meng, Yanyan and Xie, Saiyang and Deng, Wei},
  title = {Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice},
  journal = {Cardiovascular Research},
  year = {2025},
  doi = {10.1093/cvr/cvaf005}
}
Kostenlos starten →